2 weeks Ago By Defense World Staff
Alliancebernstein L.P. boosted its holdings in Cellebrite DI Ltd.
(NASDAQ:CLBT – Free Report) by 109.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,633 shares of the company’s stock after acquiring an additional 14,981 shares during the quarter.
Alliancebernstein L.P.’s holdings in Cellebrite DI were worth $631,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of CLBT. R Squared Ltd acquired a new position in shares of Cellebrite DI in the 4th quarter worth $100,000. Polen Capital Management LLC acquired a new stake in Cellebrite DI during the 4th quarter worth about $222,000.
Victory Capital Management Inc. purchased a new stake in Cellebrite DI during the fourth quarter valued at about $234,000. HighTower Advisors LLC purchased a new stake in Cellebrite DI during the fourth quarter valued at about $274,000.
Finally, Pictet Asset Management Holding SA acquired a new position in shares of Cellebrite DI in the fourth quarter worth about $283,000. 45.88% of the stock is owned by institutional investors and hedge funds.
Cellebrite DI Stock PerformanceShares of CLBT opened at $18.90 on Friday. The firm has a market cap of $4.
53 billion, a PE ratio of -13.60, a PEG ratio of 4.27 and a beta of 1.
44. The firm’s 50 day moving average price is $18.99 and its 200 day moving average price is $20.
08. Cellebrite DI Ltd. has a twelve month low of $10.
25 and a twelve month high of $26.30. Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its earnings results on Thursday, February 13th.
The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.
03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.
70%. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.
3 earnings per share for the current fiscal year. Wall Street Analysts Forecast GrowthSeveral research firms recently weighed in on CLBT. Needham & Company LLC reissued a “buy” rating and set a $28.
00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Lake Street Capital upped their target price on Cellebrite DI from $17.00 to $26.
00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $24.
00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.
com, the stock currently has an average rating of “Buy” and a consensus price target of $23.43.Check Out Our Latest Research Report on Cellebrite DIAbout Cellebrite DI (Free Report)Cellebrite DI Ltd.
develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.See AlsoFive stocks we like better than Cellebrite DIWhat Are Trending Stocks? Trending Stocks ExplainedJ.
B. Hunt Transport Overcorrects Into a Buying OpportunityWhat Are Treasury Bonds?AppLovin: Can Record Profits Overcome Market Skepticism?5 discounted opportunities for dividend growth investorsMarketBeat Week in Review – 04/14 – 04/18Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd.
(NASDAQ:CLBT – Free Report)..
